GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

Zantac was originated by GSK and launched by the company in the early 1980s, which sold it as a prescription and over-the-counter (OTC) product for indications like heartburn and acid indigestion ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

The US Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups.

The current head, John Crowley, a biotech executive and rare disease advocate, took over in March. GSK has spent slightly ...

Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

"Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product ... GSK opened 1.9-percent lower in London following the results update. Over-the ...

Phenylephrine is widely used in a variety of over-the-counter flu and cold medicines, including popular products such as Benadryl ... the ingredient Companies such as Procter & Gamble and GSK were ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.